Rani Therapeutics Holdings, Inc.

Rani Therapeutics Holdings, Inc.verified

RANI

Price:

$2.08

Market Cap:

$119.45M

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatm...[Read more]

Industry

Biotechnology

IPO Date

2021-07-30

Stock Exchange

NASDAQ

Ticker

RANI

The Current Ratio as of November 2024 (TTM) for Rani Therapeutics Holdings, Inc. (RANI) is 1.60

According to Rani Therapeutics Holdings, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 1.60. This represents a change of -50.55% compared to the average of 3.24 of the last 4 quarters.

Rani Therapeutics Holdings, Inc. (RANI) Historical Current Ratio (quarterly & annually)

How has RANI Current Ratio performed in the past?

The mean historical Current Ratio of Rani Therapeutics Holdings, Inc. over the last ten years is 18.32. The current 1.60 Current Ratio has changed 774.37% with respect to the historical average. Over the past ten years (40 quarters), RANI's Current Ratio was at its highest in in the December 2021 quarter at 45.30. The Current Ratio was at its lowest in in the March 2020 quarter at 0.

Quarterly (TTM)
Annual

Average

18.32

Median

14.12

Minimum

4.84

Maximum

45.30

Rani Therapeutics Holdings, Inc. (RANI) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Rani Therapeutics Holdings, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 220.85%

Maximum Annual Current Ratio = 45.30

Minimum Annual Increase = -69.63%

Minimum Annual Current Ratio = 4.84

Quarterly (TTM)
Annual
YearCurrent RatioChange
20236.36-69.63%
202220.96-53.73%
202145.30220.85%
202014.12191.48%

Rani Therapeutics Holdings, Inc. (RANI) Average Current Ratio

How has RANI Current Ratio performed in the past?

The current Current Ratio of Rani Therapeutics Holdings, Inc. (RANI) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

24.21

5-year avg

18.32

10-year avg

18.32

Rani Therapeutics Holdings, Inc. (RANI) Current Ratio vs. Peers

How is RANI’s Current Ratio compared to its peers?

Rani Therapeutics Holdings, Inc.’s Current Ratio is less than Vincerx Pharma, Inc. (2.17), less than Tenaya Therapeutics, Inc. (5.27), greater than Corvus Pharmaceuticals, Inc. (0.92), less than ALX Oncology Holdings Inc. (4.82), less than Lyra Therapeutics, Inc. (3.64), less than Trevi Therapeutics, Inc. (7.38), greater than SQZ Biotechnologies Company (1.37), less than Protara Therapeutics, Inc. (9.85), greater than TRACON Pharmaceuticals, Inc. (0.66), greater than Vaccinex, Inc. (0.77), less than Monopar Therapeutics Inc. (5.41K), less than Miromatrix Medical Inc. (3.46), less than Surrozen, Inc. (7.40), less than Monte Rosa Therapeutics, Inc. (6.03), less than PMV Pharmaceuticals, Inc. (13.98), less than Pharvaris N.V. (19.08), less than Tyra Biosciences, Inc. (29.55), less than Molecular Partners AG (14.33), less than Cabaletta Bio, Inc. (8.11), greater than Viracta Therapeutics, Inc. (0.76), less than EyePoint Pharmaceuticals, Inc. (5.50), less than Biomea Fusion, Inc. (3.39),

Build a custom stock screener for Rani Therapeutics Holdings, Inc. (RANI) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Rani Therapeutics Holdings, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Rani Therapeutics Holdings, Inc. (RANI) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Rani Therapeutics Holdings, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Current Ratio?

How can you use the Current Ratio?

What is Rani Therapeutics Holdings, Inc.'s Current Ratio?

How is the Current Ratio calculated for Rani Therapeutics Holdings, Inc. (RANI)?

What is the highest Current Ratio for Rani Therapeutics Holdings, Inc. (RANI)?

What is the 3-year average Current Ratio for Rani Therapeutics Holdings, Inc. (RANI)?

What is the 5-year average Current Ratio for Rani Therapeutics Holdings, Inc. (RANI)?

How does the current Current Ratio for Rani Therapeutics Holdings, Inc. (RANI) compare to its historical average?